Shares of clinical research company Medpace Holdings (NASDAQ:MEDP)
fell 3.3% in the morning session after UBS downgraded the stock to 'Sell' from 'Neutral', sending shares lower. The investment bank expressed concerns that Medpace's near and mid-term financial targets appeared "overly ambitious" given a weak industry environment. UBS noted that meeting its objectives would require record bookings in the second half of the year, which seemed challenging due to several negative factors. These factors included weak biotech capital markets, fewer clinical trial starts, and muted hiring. The downgrade came despite a slight increase in the firm's price target on the stock to $305 from $300. Recent news of significant stock sales by the company's President and CFO also may have contributed to investor concerns.
Shares of clinical research company Medpace Holdings (NASDAQ:MEDP)
fell 7.5% in the afternoon session after an analyst at TD Cowen downgraded the stock to "Sell" from "Hold," citing valuation concerns following a massive rally in the previous session.
Clinical research company Medpace Holdings (NASDAQ:MEDP) announced better-than-expected revenue in Q2 CY2025, with sales up 14.2% year on year to $603.3 million. The company’s full-year revenue guidance of $2.47 billion at the midpoint came in 13% above analysts’ estimates. Its GAAP profit of $3.10 per share was 3.5% above analysts’ consensus estimates.
Wondering how the US markets performed one hour before the close of the markets on Tuesday? Discover the movers and shakers of today's session in our comprehensive analysis.
Shares of clinical research company Medpace Holdings (NASDAQ:MEDP)
jumped 49.3% in the morning session after the company reported strong second-quarter financial results and raised its full-year guidance.
Let's have a look at what is happening on the US markets in the middle of the day on Tuesday. Below you can find the top gainers and losers in today's session.
The session on Tuesday is off to an intriguing start with several stocks showing significant price gaps. Let's examine the gap up and gap down stocks in today's session.
The US market is yet to commence its session on Tuesday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements.
